» Articles » PMID: 32445271

Rapid Enzymatic Burn Debridement: A Review of the Paediatric Clinical Trial Experience

Overview
Journal Int Wound J
Date 2020 May 24
PMID 32445271
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

NexoBrid (NXB) has been proven to be an effective selective enzymatic debridement agent in adults. This manuscript presents the combined clinical trial experience with NXB in children. Hundred and ten children aged 0.5 to 18 years suffering from deep thermal burns of up to 67% total body surface area were treated with NXB in three clinical trials. Seventy-seven children were treated with NXB in a phase I/II study, where 92.7% of the areas treated achieved complete eschar removal within 0.9 days from admission. Thirty-three children (17 NXB, 16 standard of care [SOC]) participated in a phase III randomized controlled trial. All wounds treated with NXB achieved complete eschar removal. Time to complete eschar removal (from informed consent) was 0.9 days for NXB vs 6.5 days for SOC (P < .001). The incidence of surgical excision was 7.9% for NXB vs 73.3% for SOC (P < .001). Seventeen of these children participated in a phase III-b follow-up study (9 NXB and 8 SOC). The average long-term modified Vancouver Scar Scale scores were 3.4 for NXB-treated wounds vs 4.4 for SOC-treated wounds (NS). There were no significant treatment-related adverse events. Additional studies are needed to strengthen these results.

Citing Articles

The Effectiveness of an Alloplastic Epidermal Substitute in the Treatment of Burn Wounds in Children: A Comparative Clinical Study of Skin Substitutes and Silver and Paraffin Gauze Dressings.

Barbachowska A, Korzeniowski T, Surowiecka A, Tomaka P, Bugaj-Tobiasz M, Laczyk M J Clin Med. 2024; 13(23).

PMID: 39685697 PMC: 11642082. DOI: 10.3390/jcm13237238.


Role, Development, and Value of Enzymatic Debridement as Integral Component in Initial Treatment of Burn Injuries Exemplified by NexoBrid.

Mattern M, Fuchs P, Schiefer J Eur Burn J. 2024; 3(2):340-354.

PMID: 39600004 PMC: 11575367. DOI: 10.3390/ebj3020029.


Synergistic Treatment of Infected Burn Wound Utilizing Maggot Debridement and Acellular Fish Skin Grafting-A Case Report.

Borger A, Semmler L, Bergmann F, Supper P, Radtke C J Burn Care Res. 2024; 45(5):1336-1340.

PMID: 38953562 PMC: 11379142. DOI: 10.1093/jbcr/irae128.


Pediatric Facial Burn Reconstruction.

Moon T, Driscoll D Semin Plast Surg. 2024; 38(2):162-180.

PMID: 38746693 PMC: 11090663. DOI: 10.1055/s-0044-1786009.


Quality indicators for hospital burn care: a scoping review.

Suzuki D, Santana L, Avila J, Amorim F, Modesto G, Gottems L BMC Health Serv Res. 2024; 24(1):486.

PMID: 38641612 PMC: 11031897. DOI: 10.1186/s12913-024-10980-7.


References
1.
De Francisci G, Papasidero A, Spinazzola G, Galante D, Caruselli M, Pedrotti D . Update on complications in pediatric anesthesia. Pediatr Rep. 2013; 5(1):e2. PMC: 3649741. DOI: 10.4081/pr.2013.e2. View

2.
Rosenberg L, Lapid O, Bogdanov-Berezovsky A, Glesinger R, Krieger Y, Silberstein E . Safety and efficacy of a proteolytic enzyme for enzymatic burn debridement: a preliminary report. Burns. 2004; 30(8):843-50. DOI: 10.1016/j.burns.2004.04.010. View

3.
Ozcan C, Ergun O, Celik A, Corduk N, Ozok G . Enzymatic debridement of burn wound with collagenase in children with partial-thickness burns. Burns. 2002; 28(8):791-4. DOI: 10.1016/s0305-4179(02)00191-2. View

4.
Passaretti D, Billmire D . Management of pediatric burns. J Craniofac Surg. 2003; 14(5):713-8. DOI: 10.1097/00001665-200309000-00021. View

5.
Klasen H . A review on the nonoperative removal of necrotic tissue from burn wounds. Burns. 2000; 26(3):207-22. DOI: 10.1016/s0305-4179(99)00117-5. View